Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Polaris Market Research
www.polarismarketresearch.com
likhil.g@polarismarketresearch.com
1-646-568-9980
30 Wall Street 8th Floor New York City, NY 10005 United States


Bookmark and Share
Atopic Dermatitis Market Size Historical Growth,Opportunities and Forecast To 2025
PolarisMarketResearch.com adds aGlobal Atopic Dermatitis Market research report for the period of 2025 focuses on the major drivers and restraints for the global key players providing analysis of the forecasts and geographic regions of the market.

BriefingWire.com, 9/19/2018 - The Global Atopic Dermatitis Market Size is anticipated to gain traction due to increasing research and development for developing new drugs that would be an effective treatment for the atopic dermatitis.

Request for Sample of This Research Report @ [URL]https://bit.ly/2DbWnnp[/URL]

Top Key Players:-

Novartis International AG.

Pfizer Inc.

Sonafi SA

Galderma SA

Allergen plc.

Connectics Corporation

Fujisawa Healthcare

Encore Dermatology Inc.

Velite Pharmaceuticals

Make an inquiry before buying this report @ [URL]https://www.polarismarketresearch.com/industry-analysis/global-atopic-dermatitis-market-size/inquire-before-buying[/URL]

Atopic dermatitis is persistent skin disease that affects large number of world’s population. It is an allergic hypersensitivity that is associated with inhalant allergies, and a chronic dermatitis. Commonly, atopic dermatitis is a hereditary component. It is diagnosed by appearance and distribution of rashes on the person’s body with the history of asthma. Atopic dermatitis is a non-contagious disease and can be identified by the swelling and redness on the skin. Atopic dermatitis occurs in all age groups but majorly affects infants and young children. Atopic dermatitis treatment involves the use of oral antibiotics, steroid pills, photo therapy, biological treatments like monoclonal antibody, and in some cases dietary changes that can cause food allergy.

Recently, various new drugs developed are referred as immune modulators. For instance, Dupilumab (Duxipent) was recently approved by the FDA for the treatment of severe atopic dermatitis in adults. It is an anti-IL-4 antibody that is injected in the patient’s body and has shown promising result in controlling atopic dermatitis. Hence, continuous new product development for treating atopic dermatitis has created new pace in atopic dermatitis market.

Browse Full Report @ [URL]https://www.polarismarketresearch.com/industry-analysis/global-atopic-dermatitis-market-size/[/URL]

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2024 Proserve Technology, Inc.